Chapter Three - CRISPR–Cas9 for Drug Discovery in Oncology

• Autores: Sylvie Guichard
• Localización: Annual reports in medicinal chemistry, ISSN 0065-7743, Vol 50, 2017, págs. 61-85
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Abstract Drug discovery is a complex enterprise bringing together a variety of skills and techniques. Oncology drug discovery has taken advantage of cancer genetics to identify drug molecules tailored to specific subset of tumors which has proven highly beneficial to patients. Modifying the genome to understand better cancer genetics has been instrumental in this process. CRISPR–Cas9 is a new programmable gene-editing tool which expand dramatically the scope of genetic manipulation to decipher cancer biology. CRISPR–Cas9 has taken drug discovery by storm and many facets of drug discovery could benefit from this technology. This chapter will briefly touch on the mechanism of genome editing and the growing number of modified Cas9 enzymes before presenting how CRISPR–Cas9 is impacting different aspects of drug discovery namely target identification, validation and deconvolution, reagent generation and drug synthesis, assessment of drug sensitivity and drug resistance, as well as drug disposition and toxicology.